Soligenix, Inc. Common Stock (SNGX) Stock Price

SNGXStock

$0.38−87.69%52W

Market Cap$8.20M

P/E—

PEG Ratio—

Div yield—

Beta2.09

SNGX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-79.16%

Price vs S&P 500 (4W)-1.73%

VGM Score25.36

Book Value / Share (Quarterly)$0.29

P/TBV (Annual)10.22x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-47.39%

Cash Flow / Share (Quarterly)$-1.03

Price vs S&P 500 (YTD)-84.70%

Gross Margin (TTM)8.75%

Net Profit Margin (TTM)-1424.53%

EPS (TTM)$-1.97

10-Day Avg Trading Volume0.31M

EPS Excl Extra (TTM)$-1.97

Revenue Growth (5Y)-51.89%

EPS (Annual)$-2.14

ROI (Annual)-209.37%

Gross Margin (Annual)0.00%

Net Profit Margin (5Y Avg)-2277.89%

Cash / Share (Quarterly)$0.57

ROA (Last FY)-119.98%

EBITD / Share (TTM)$-1.68

ROE (5Y Avg)-248.72%

Operating Margin (TTM)-1574.25%

Cash Flow / Share (Annual)$-1.02

P/B Ratio2.72x

P/B Ratio (Quarterly)3.94x

Net Income / Employee (Annual)$-852,300

EV / Revenue (TTM)4.78x

Net Interest Coverage (TTM)-1725.75x

ROA (TTM)-131.93%

EV / EBITDA (TTM)1.95x

EPS Incl Extra (Annual)$-2.14

Current Ratio (Annual)2.39x

Quick Ratio (Quarterly)1.69x

3-Month Avg Trading Volume5.30M

52-Week Price Return-87.69%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$1.83

P/S Ratio (Annual)70.29x

Asset Turnover (Annual)0.01x

52-Week High$3.22

Operating Margin (5Y Avg)-2540.96%

EPS Excl Extra (Annual)$-2.14

CapEx CAGR (5Y)-10.08%

Tangible BV CAGR (5Y)6.73%

26-Week Price Return-67.23%

Quick Ratio (Annual)2.15x

13-Week Price Return-61.26%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.81x

Enterprise Value$2.36M

Revenue / Share Growth (5Y)-54.25%

Asset Turnover (TTM)0.05x

Book Value / Share Growth (5Y)-12.22%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-7267.90%

Cash / Share (Annual)$0.79

3-Month Return Std Dev91.24%

Gross Margin (5Y Avg)17.76%

Net Income / Employee (TTM)$-842,600

ROE (Last FY)-209.37%

Net Interest Coverage (Annual)-14.55x

EPS Basic Excl Extra (Annual)$-2.14

P/FCF (TTM)3.06x

Receivables Turnover (TTM)1.39x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.97

Receivables Turnover (Annual)1.39x

ROI (TTM)-246.04%

P/S Ratio (TTM)16.98x

Pretax Margin (5Y Avg)-2441.11%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.83

Price vs S&P 500 (52W)-106.24%

Year-to-Date Return-71.88%

5-Day Price Return-6.89%

EPS Normalized (Annual)$-2.14

ROA (5Y Avg)-83.64%

Net Profit Margin (Annual)-6925.17%

Month-to-Date Return0.78%

Cash Flow / Share (TTM)$-1.38

EBITD / Share (Annual)$-2.28

Operating Margin (Annual)-7907.77%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-130.65%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.97

P/TBV (Quarterly)10.22x

P/B Ratio (Annual)2.55x

Inventory Turnover (TTM)29.64x

Pretax Margin (TTM)-1547.28%

Book Value / Share (Annual)$0.52

Price vs S&P 500 (13W)-63.21%

Beta2.09x

Revenue / Share (TTM)$0.00

ROE (TTM)-246.04%

52-Week Low$0.28

vGradeB

gGradeF

mGradeF

vgmGradeD

SNGX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 7, 2026	-$0.09	-$0.13	-42.44%(-$0.04)
Q1 2026	May 8, 2026	-$0.24	-$0.28	-16.67%(-$0.04)
Q3 2025	Nov 7, 2025	-$0.48	-$0.58	-20.83%(-$0.10)
Q2 2025	Aug 14, 2025	-$1.05	-$0.82	+21.90%(+$0.23)

SNGX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
SNGXSoligenix, Inc. Common Stock	B	F	F	$0.38
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Soligenix, Inc. Common Stock

Soligenix is a biopharmaceutical company developing therapeutics and vaccines for rare diseases and public health threats with unmet medical needs. Operating through Specialized BioTherapeutics and Public Health Solutions segments, the company generates primary revenues from Public Health Solutions, including RiVax (a ricin toxin vaccine candidate), SGX943 (for antibiotic-resistant and emerging infectious diseases), and vaccine research programs targeting Ebola, Marburg, and SARS-CoV-2.